0001104659-23-103527.txt : 20230925
0001104659-23-103527.hdr.sgml : 20230925
20230925162757
ACCESSION NUMBER: 0001104659-23-103527
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230921
FILED AS OF DATE: 20230925
DATE AS OF CHANGE: 20230925
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sorrento Therapeutics, Inc.
CENTRAL INDEX KEY: 0000850261
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39852
FILM NUMBER: 231276120
BUSINESS ADDRESS:
STREET 1: 4955 DIRECTORS PLACE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-203-4100
MAIL ADDRESS:
STREET 1: 4955 DIRECTORS PLACE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER NAME:
FORMER CONFORMED NAME: QUIKBYTE SOFTWARE INC
DATE OF NAME CHANGE: 19920703
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Scilex Holding Co
CENTRAL INDEX KEY: 0001820190
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 960 SAN ANTONIO ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94303
BUSINESS PHONE: (650) 516-4310
MAIL ADDRESS:
STREET 1: 960 SAN ANTONIO ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94303
FORMER COMPANY:
FORMER CONFORMED NAME: Scilex Holding Company/DE
DATE OF NAME CHANGE: 20221117
FORMER COMPANY:
FORMER CONFORMED NAME: Vickers Vantage Corp. I
DATE OF NAME CHANGE: 20200804
4
1
tm2326753-1_4.xml
FORM 4
X0508
4
2023-09-21
1
0001820190
Scilex Holding Co
SCLX
0000850261
Sorrento Therapeutics, Inc.
4955 DIRECTORS PLACE
SAN DIEGO
CA
92121
0
0
1
0
0
Common Stock
2023-09-21
4
S
0
60068585
D
1917210
D
Warrants to Purchase Common Stock
11.50
2023-09-21
4
S
0
4490617
D
2022-11-10
2027-11-10
Common Stock
4490617
0
D
Pursuant to that certain Stock Purchase Agreement, dated September 21, 2023, between the Reporting Person and Scilex Holding Company ("Scilex"), Scilex purchased the following securities from the Reporting Person for an aggregate purchase price of (a) $10 million in cash; plus (b) the assumption by Scilex of $100 million of debt under the Reporting Person's non-amortizing super-priority senior secured debtor-in-possession term loan facility; plus (c) the assumption by Scilex of certain obligations of the Reporting Person for legal fees and expenses in the amount of approximately $12.25 million; plus (d) a credit bid of approximately $23 million owed to Scilex under the Reporting Person's non-amortizing super-priority junior secured term loan facility: (i) 60,068,585 shares of Common Stock of Scilex; (ii) 29,057,097 shares of Series A Preferred Stock of Scilex; and (iii) warrants exercisable for 4,490,617 shares of Common Stock of Scilex.
/s/ Mohsin Y. Meghji
2023-09-25